G&S Capital’s Biogen BIIB Stock Holding History

G&S Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,800	Closed	-$1.94M	–	117
2023 Q2	$1.94M	Sell	6,800 -107	-2%	-$31.9K	0.93%	43
2023 Q1	$1.92M	Buy	6,907 +148	+2%	+$41K	0.85%	39
2022 Q4	$1.87M	Buy	+6,759	New	+$1.91M	0.83%	37

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

G&S Capital's BIIB Position: Q3 2023 in Review

G&S Capital sold out of Biogen (BIIB) in Q3 2023, closing a stake of 6,800 shares — an estimated $1.94M sold.

G&S Capital first reported a position in BIIB in Q4 2022 and held it in 3 quarters. The position peaked at $1.94M in Q2 2023. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.

G&S Capital reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
G&S Capital sold 6,800 Biogen shares in Q3 2023, an estimated $1.94M.
G&S Capital first reported a position in Biogen in Q4 2022 and held it in 3 quarters.
G&S Capital's Biogen position peaked at $1.94M in Q2 2023.
965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.

Based on G&S Capital's 13F filing for Q3 2023, filed 12 Oct 2023.